Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 24 March 2025

Created: 24 March 2025

Last Updated: 24 March 2025

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern

Posted: 2025-03-24 04:01:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related Bing News Search Results

Press Release: Opthea Announces COAST Phase 3 Trial Topline Results - Newscast

Opthea, UNITY Fail to Unseat Regeneron’s Eylea in Vision Disorders

Tue, 25 Mar 2025 05:28:00 GMT The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s biosimilar from the U.S.

Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty

Mon, 24 Mar 2025 06:18:00 GMT Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces potential investor obligations.

Opthea Announces COAST Phase 3 Trial Topline Results

Mon, 24 Mar 2025 05:15:00 GMT (MENAFN- EIN Presswire) COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its ...

Opthea COAST trial misses primary endpoint, enters talks with DFA Investors

Mon, 24 Mar 2025 02:40:00 GMT Opthea (OPT) announced results from its global Phase 3 clinical trial COAST in patients with wet AMD. The global COAST Phase 3 trial evaluated ...

Opthea's eye disease drug defeated by Eylea in phase 3, leaving biotech to mull future

Mon, 24 Mar 2025 02:25:00 GMT Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was making preparations for the potential launch of a new eye disease drug onto ...